ITM Isotopen Technologien München

Executive Summary

ITM Isotopen Technologien München (ITM) is a private German radiopharmaceutical company founded in 2004, headquartered in Munich, and dedicated to developing precision oncology diagnostics and therapeutics. The company leverages its proprietary radioisotope production technology to supply high-quality medical isotopes globally. ITM's lead therapeutic candidate, ITM-11 (177Lu-edotreotide), targets somatostatin receptor-positive neuroendocrine tumors (NETs) and is currently in a Phase 3 clinical trial (COMPOSE) evaluating its efficacy and safety. The company also offers a diagnostic generator (68Ga-edotreotide) for PET imaging, enabling a theranostic approach. With a strong focus on hard-to-treat cancers, ITM's integrated platform positions it as a key player in the rapidly growing radiopharmaceutical market. ITM's late-stage pipeline and proprietary isotope supply chain underpin its competitive advantage. The upcoming Phase 3 data readout for ITM-11 in NETs represents a major catalyst, potentially supporting regulatory filings in the US and EU. The company is also expanding its production capacity with a new facility in Munich to meet global demand. Given the unmet need in NETs and the increasing adoption of radiopharmaceuticals, ITM's prospects are promising. However, execution risks include trial outcomes and manufacturing scale-up. Overall, ITM is a compelling investment opportunity in the radiopharma space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 COMPOSE trial data readout for ITM-11 in NETs70% success
• H1 2027Regulatory submission (NDA/MAA) for ITM-11 in NETs65% success
• Q2 2026Commercial launch of new production facility in Munich90% success